Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 0.78 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.78 |
| ▸ | FAP | Q12884 | 4/20 | 0.74 |
| ▸ | POU2F2 | P09086 | 1/20 | 0.74 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.74 |
| ▸ | POU2F1 | P14859 | 1/20 | 0.74 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.74 |
| ▸ | HRH2 | P25021 | 1/20 | 0.74 |
| ▸ | MC4R | P32245 | 1/20 | 0.74 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.74 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.74 |
| ▸ | GHSR | Q92847 | 1/20 | 0.74 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4813357 | 1.00 | DPP4 (0.78) | DPP4CHRM1FAPPOU2F2ADORA3 | |
| SCHEMBL4808537 | 0.93 | DPP4 (0.74) | DPP4CHRM1FAPPOU2F2ADORA3 | |
| SCHEMBL4808547 | 0.93 | DPP4 (0.74) | DPP4CHRM1FAPPOU2F2ADORA3 | |
| SCHEMBL4812709 | 0.91 | DPP4 (0.66) | DPP4CHRM1FAPPOU2F2ADORA3 | |
| SCHEMBL8283962 | 0.90 | DPP4 (0.63) | DPP4CHRM1FAPPOU2F2ADORA3 | |
| SCHEMBL4816771 | 0.88 | DPP4 (0.70) | DPP4CHRM1FAPPOU2F2ADORA3 | |
| SCHEMBL5842422 | 0.88 | DPP4 (1.00) | DPP4CHRM1FAPPOU2F2ADORA3 | |
| SCHEMBL5842437 | 0.88 | DPP4 (1.00) | DPP4CHRM1FAPPOU2F2ADORA3 | |
| SCHEMBL2918142 | 0.87 | DPP4 (0.76) | DPP4CHRM1FAPPOU2F2ADORA3 | |
| SCHEMBL4813027 | 0.86 | DPP4 (0.59) | DPP4CHRM1FAPPOU2F2ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7393847-B2 | Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions | BOEHRINGER INGLEHEIM INTERNATIONAL GMBH (DE) | 2008-07-01 | — | — | US | claimed |
| US-20050203095-A1 | Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-09-15 | — | — | US | claimed |
| US-7432262-B2 | Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-10-07 | — | — | US | disclosed |
| US-7432262-B2 | Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-10-07 | — | — | US | disclosed |
| US-7393847-B2 | Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions | BOEHRINGER INGLEHEIM INTERNATIONAL GMBH (DE) | 2008-07-01 | — | — | US | disclosed |
| US-7393847-B2 | Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions | BOEHRINGER INGLEHEIM INTERNATIONAL GMBH (DE) | 2008-07-01 | — | — | US | disclosed |
| US-20070142383-A1 | Imidazopyridazinediones, Their Preparation And Their Use As Pharmaceutical Compositions | ECKHARDT MATTHIAS | 2007-06-21 | — | — | US | disclosed |
| US-20070142383-A1 | Imidazopyridazinediones, Their Preparation And Their Use As Pharmaceutical Compositions | ECKHARDT MATTHIAS | 2007-06-21 | — | — | US | disclosed |
| US-20050203095-A1 | Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142383-A1 | Imidazopyridazinediones, Their Preparation And Their Use As Pharmaceutical Compositions | DPP4, DPP3, DPP7 | DPP4 1/4885CHRM1 624/4885FAP 24/4885 |
| US-20050203095-A1 | Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions | DPP4, DPP3, DPP7 | DPP4 1/4885CHRM1 611/4885FAP 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.